ArticleThe Journal of experimental medicine2017
Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.Leukemia · 2026Article
- A specific stem cell program and CD112 immunological axis dysfunctions underpinning monosomy 7-associated myeloid neoplasms.Signal transduction and targeted therapy · 2026Article
- IKAROS Gene Regulatory Network Reveal ERG as a Vulnerability in B-cell Acute Lymphoblastic Leukemia.bioRxiv : the preprint server for biology · 2025Article
- IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies.Nature communications · 2025Article
- Article
- Article
- Concepts in B cell acute lymphoblastic leukemia pathogenesis.Journal of leukocyte biology · 2024Review
- IKAROS Family Transcription Factors in Lymphocyte Differentiation and Function.Advances in experimental medicine and biology · 2024Review
- Ikaros is a principal regulator of AireScience immunology · 2023Article
- Integrins and the Metastasis-like Dissemination of Acute Lymphoblastic Leukemia to the Central Nervous System.Cancers · 2023Review
- IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater?International journal of molecular sciences · 2023Review
- IRF4 deficiency vulnerates B-cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity.Cell death and differentiation · 2022Article
- Ikaros Regulates microRNA Networks in Acute Lymphoblastic Leukemia.Epigenomes · 2022Article
- High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion.Molecular oncology · 2022Article
- Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.International journal of molecular sciences · 2021Review
- Article
- Review
- Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm.Genes, chromosomes & cancer · 2020Article
- Regulation of Small GTPase Rab20 by Ikaros in B-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2020Article
- Identification and characterization of a murine model of BCR‑ABL1+ acute B‑lymphoblastic leukemia with central nervous system metastasis.Oncology reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Hilde SchjervenDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143 Hilde.Schjerven@ucsf.edu Seth.Frietze@med.uvm.edu.ORCID 0000-0001-9287-3375
Etapong F AyongabaDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0003-2960-9808
Ali AghajanirefahDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143.
Jami McLaughlinDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095.
Donghui ChengEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095.
Huimin GengDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143.
Joseph R BoydDepartment of Biochemistry and University of Vermont Cancer Center, University of Vermont, Burlington, VT 05405.ORCID 0000-0002-8969-9676
Linn M EggesbøDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143.
Ida LindemanDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0001-8343-2842
Jessica L HeathDepartment of Pediatrics, University of Vermont, Burlington, VT 05405.ORCID 0000-0003-1771-2242
Eugene ParkDepartment of Laboratory Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0001-8432-5168
Owen N WitteDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095.ORCID 0000-0003-4461-4533
Stephen T SmaleDepartment of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, CA 90095.
Seth FrietzeDepartment of Medical Laboratory and Radiation Science, University of Vermont, Burlington, VT 05405 Hilde.Schjerven@ucsf.edu Seth.Frietze@med.uvm.edu.
Markus MüschenDepartment of Systems Biology, Beckman Research Institute and City of Hope Comprehensive Cancer Center, Pasadena, CA 91016.
University of California, San Francisco · USUniversity of California, Los Angeles · USUniversity of Vermont · USCity of Hope · USUniversity of Vermont Medical Center · US
Funding
Metabolic gatekeepers in B-cell malignanciesR35CA197628 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2016 to 2026
$11.7MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MREGULATION OF TDT EXPRESSION DURING LYMPHOPOIESISR01DK043726 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SMALE, STEPHEN T · 1996 to 2014
$4.2MPRE-B CELL RECEPTOR SIGNALING IN ACUTE LYMPHOBLASTIC LEUKEMIAR01CA137060 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2009 to 2016
$2.7MCD25-mediated feedback control of BCR-signaling and its oncogenic mimicsR01CA213138 · NCI · YALE UNIVERSITY · PI MÜSCHEN, MARKUS · 2017 to 2022
$1.9MAID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemiaR01CA139032 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2009 to 2013
$1.6MNegative feedback signaling in tyrosine kinase-driven leukemiaR01CA172558 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972kTargeting BCL6 in tyrosine kinase-driven leukemiaR01CA169458 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MÜSCHEN, MARKUS · 2013 to 2015
$972kMechanism of Ikaros Tumor Suppression in progenitor B cell leukemiaR21CA209229 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRIETZE, SETH E, SCHJERVEN, HILDE · 2016 to 2017
$420kHoward Hughes Medical InstituteNCI NIH HHS R01 CA137060NCI NIH HHS R01 CA139032NCI NIH HHS R01 CA157644NCI NIH HHS R01 CA169458NCI NIH HHS R01 CA172558NCI NIH HHS R01 CA213138NCI NIH HHS R21 CA209229NCI NIH HHS R35 CA197628NIDDK NIH HHS R01 DK043726
Abstract
Inactivation of the tumor suppressor gene encoding the transcriptional regulator Ikaros (
Indexed as
AnimalsAntigens, CD34Cell CycleCell Line, TumorFusion Proteins, bcr-ablGene Expression Regulation, LeukemicHumansIkaros Transcription FactorLeukosialinMiceMice, Inbred C57BLPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-kitTumor Suppressor ProteinsAntigens, CD34BCR-ABL1 fusion protein, humanFusion Proteins, bcr-ablIkaros Transcription FactorIKZF1 protein, humanLeukosialinProto-Oncogene Proteins c-kitTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.